Serum CEA is the most important tumor marker for the presence of subclinical hepatic or pulmonary metastases, and elevated pretreatment serum CEA levels were significantly associated with poor prognosis in rectal cancer patients (20, 21). This evidence concerns the gene CEACAM5 and neoplasm.